Calumet

Calumet shares rose to a new 52-week high of $51.51 and are currently trading at $51.43 with a market capitalization of about $4.5 billion. The stock gained 207.95% over the past year and 150% year-to-date, but InvestingPro warns the shares may be overvalued. Calumet reported mixed Q2 2026 results: revenue of $1.44 billion beat estimates, but adjusted earnings showed a loss of $1.09 per share; adjusted EBITDA was $175 million and operating cash flow exceeded $90 million. S&P Global upgraded the rating to B-, and several analysts raised their price targets on the back of strong specialty oil and biofuel margins. » More on de.investing.com

S&P Global Ratings has raised Calumet’s issuer rating from CCC+ to B- and upgraded ratings on individual issues to B+ (senior secured) and B- (unsecured); the outlook is stable. The move reflects better-than-expected results in the first half of 2026, improved credit metrics and higher revenue and cash flow driven by strong margins in specialty oils, fuels and renewable fuels. S&P expects adjusted debt/EBITDA of about 6x–7x with a tendency to improve, notes SAF capacity expansions at Montana Renewables and cites upcoming bond maturities and increased RIN obligations as risks to monitor. » More on de.investing.com

Shares of Calumet Specialty Products Partners rose to a 52-week high of $49.17, lifting market capitalization to $4.31 billion, accompanied by a one‑year return of 265.46% and a year‑to‑date gain of 143%. InvestingPro rates the stock as above its fair value. For Q2 the company reported revenues of $1.44 billion (above expectations), adjusted EPS of -$1.09 (below expectations), adjusted EBITDA of $175 million and operating cash flow of more than $90 million. TD Cowen raised its price target from $34 to $40, kept the rating at “Hold” and expects a strong second half as base oil margins normalize. » More on de.investing.com